Valuation BLS Pharmaceuticals Limited OTC Markets
Stocks
PBIM.D
AU0000477796
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | - |
Company Valuation: BLS Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 6.401 | 17.92 | 7.682 | 38.03 | 10.23 | 88.76 |
| Change | - | 180% | -57.14% | 395.11% | -73.09% | 767.35% |
| Enterprise Value (EV) 1 | 4.701 | 16.32 | 5.514 | 34.75 | 9.916 | 82.62 |
| Change | - | 247.2% | -66.22% | 530.16% | -71.46% | 733.27% |
| P/E | -10.8x | -35x | -30x | -13.9x | -0.72x | 17.8x |
| PBR | 2.5x | 9.53x | 4.07x | 2.51x | 2.84x | 7.15x |
| PEG | - | 2.6x | 0.6x | -0x | -0x | -0x |
| Capitalization / Revenue | 2.76x | 8.13x | 3.09x | 7.17x | 1.06x | 3.03x |
| EV / Revenue | 2.02x | 7.4x | 2.22x | 6.55x | 1.03x | 2.82x |
| EV / EBITDA | -15.6x | -124x | -38.9x | -20.1x | -9.16x | 15.3x |
| EV / EBIT | -14.4x | -109x | -36.2x | -18.9x | -8.75x | 16.2x |
| EV / FCF | 20.4x | 34.5x | 12.4x | -63.8x | -3.81x | 29.2x |
| FCF Yield | 4.9% | 2.9% | 8.05% | -1.57% | -26.3% | 3.42% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.009265 | -0.007999 | -0.003999 | -0.0144 | -0.069 | 0.023 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 2.322 | 2.204 | 2.485 | 5.305 | 9.643 | 29.28 |
| EBITDA 1 | -0.3009 | -0.132 | -0.1416 | -1.726 | -1.082 | 5.402 |
| EBIT 1 | -0.3257 | -0.1497 | -0.1525 | -1.836 | -1.133 | 5.099 |
| Net income 1 | -0.5931 | -0.4957 | -0.2365 | -1.94 | -13.33 | 4.901 |
| Net Debt 1 | -1.7 | -1.602 | -2.168 | -3.287 | -0.3176 | -6.134 |
| Reference price 2 | 0.1000 | 0.2800 | 0.1200 | 0.2000 | 0.0500 | 0.4100 |
| Nbr of stocks (in thousands) | 64,015 | 64,015 | 64,015 | 190,165 | 204,665 | 216,483 |
| Announcement Date | 9/30/20 | 9/30/21 | 9/30/22 | 9/29/23 | 9/30/24 | 9/30/25 |
1AUD in Million2AUD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -23.34x | 351.51x | -21.46x | -.--% | 39.58B | ||
| 46.99x | 4.73x | 30.33x | -.--% | 34.69B | ||
| 25.1x | 2.78x | 12.03x | -.--% | 34.42B | ||
| 27.15x | 7.96x | 19.98x | 0.42% | 27.11B | ||
| 31.75x | 5.12x | 23.3x | -.--% | 15.36B | ||
| 24.41x | 2.07x | 9.09x | 1.1% | 14.05B | ||
| 24.03x | 1.91x | 11.58x | -.--% | 13.02B | ||
| -32.61x | 124.59x | -35.46x | -.--% | 11.76B | ||
| Average | 15.44x | 62.58x | 6.17x | 0.19% | 23.75B | |
| Weighted average by Cap. | 16.14x | 84.13x | 7.25x | 0.14% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- BLS Stock
- PBIM.D Stock
- Valuation BLS Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
















